Smithfield Trust’s Ionis Pharmaceuticals IONS Stock Holding History

Smithfield Trust’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-15	Closed	-$1K	–	1117
2020 Q2	$1K	Buy	+15	New	+$834	﹤0.01%	1012
2015 Q3	–	Sell	-2,110	Closed	-$121K	–	804
2015 Q2	$121K	Sell	2,110 -70	-3%	-$4.45K	0.02%	361
2015 Q1	$139K	Buy	+2,180	New	+$148K	0.03%	357

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Smithfield Trust's IONS Position: Q3 2020 in Review

Smithfield Trust sold out of Ionis Pharmaceuticals (IONS) in Q3 2020, closing a stake of 15 shares — an estimated $1K sold.

Smithfield Trust first reported a position in IONS in Q1 2015 and held it in 3 quarters. The position peaked at $139K in Q1 2015. 367 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

Smithfield Trust reported no remaining Ionis Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Smithfield Trust sold 15 Ionis Pharmaceuticals shares in Q3 2020, an estimated $1K.
Smithfield Trust first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 3 quarters.
Smithfield Trust's Ionis Pharmaceuticals position peaked at $139K in Q1 2015.
367 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on Smithfield Trust's 13F filing for Q3 2020, filed 16 Nov 2020.